Fig. 1 · Structure

Documents & Downloads

Ozagrel (OKY-046)

Cat. No. A10688 CAS 82571-53-7

TXAS inhibitor

Ozagrel is a potent and selective thromboxane A2 synthetase inhibitor with an IC50 of 4 nM.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
Thromboxane A2 synthetase 11 nM

Cellular Effect

Cell Line Activity Value Description Reference
Platelet IC50 0.36 mM Antiplatelet activity in rabbit platelet rich plasma assessed as inhibition of ADP-induced platelet aggregation after 5 mins by aggregometry [PMID: 21993151]
Platelet IC50 0.36 mM Antiplatelet activity in rabbit platelet rich plasma assessed as inhibition of ADP-induced aggregation treated for 5 mins prior to ADP-challenge 10.1039/C3MD20352B
Platelet IC50 144.1 μM Anti-platelet activity in rabbit platelet-rich plasma assessed as inhibition of ADP-induced platelet aggregation incubated for 5 mins at 37 degC by aggregometry 10.1039/C4MD00022F
Platelet IC50 53.1 μM Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 2 mins followed by arachidonic acid addition by turbidimetric method relative to control [PMID: 28453995]

Ozagrel (OKY-046) Research Summary

This section summarizes 1 in vitro study and 2 in vivo studies of Ozagrel (OKY-046) from 3 published references. In vitro models include microsomes from mouse liver. In vivo models include male stroke-prone spontaneously hypertensive rats (SHRSP/Kpo).

Ozagrel (OKY-046) In Vitro Studies

Ozagrel was evaluated in microsomes from mouse liver by incubation with the reaction mixture. Across 0.001–1.0 mg/mL, Ozagrel did not inhibit CYP2E1 activity. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Ozagrel and CYP2E1 Activity in Mouse Liver Microsomes

Cell-based study · Microsomes from mouse liver [1]

Microsomes from mouse liver were incubated with Ozagrel at 0.001–1.0 mg/mL. Ozagrel did not inhibit CYP2E1 activity at any tested dose.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CYP2E1 activityReported result Ozagrel, at any dose (0.001–1.0 mg/mL), did not inhibit CYP2E1 activity.[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.001–1.0 mg/mL
Method
incubated with the reaction mixture
Reported limits
Not stated in the sentences used: schedule, vehicle.
Methods and source locations

Compound reported in the paper: Ozagrel

Evidence for Ozagrel as the hydrate, hydrochloride form reported in the paper, not the free base/neutral form supplied as A10688; no salt equivalence, dose conversion or lot validation.

Methods > CYP2E1 activity (S44, S45, S47); Results > Changes in liver glutathione content and CYP 2E1 activity in hepatic microsomes (S89); Figure 5 legend (S134)

CYP2E1 activity: CYP2E1 activity; comparator: without ozagrel — Methods > CYP2E1 activity (S47); Results > Changes in liver glutathione content and CYP 2E1 activity in hepatic microsomes (S89)

Ozagrel (OKY-046) In Vivo Studies

Ozagrel administered in drinking water exacerbated urinary albumin excretion in male stroke-prone spontaneously hypertensive rats (SHRSP/Kpo). In female ICR mice with adenomyosis, Ozagrel was administered intraperitoneally at low or high doses. Compared with untreated mice, both Ozagrel dose groups had significantly less myometrial infiltration. [2,3]

Ozagrel and Urinary Albumin Excretion in Hypertensive Rats

Animal study · male stroke-prone spontaneously hypertensive rats (SHRSP/Kpo) [2]

Male stroke-prone spontaneously hypertensive rats (SHRSP/Kpo) received Ozagrel in drinking water. Ozagrel exacerbated urinary albumin excretion.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
urinary albumin excretion (UAE)urinary albumin excretion 3.5 mmol/L; provided for 5 weeks: 8.4 ± 1.3 mg/day[2]

Conditions shared by the study groups

Route
drinking water
Treatment course
provided for 5 weeks
Vehicle
water
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Ozagrel 3.5 mmol/Luntreatedboth tempol and ozagrel exacerbated the UAE; ozagrel: 8.4 ± 1.3 mg/day[2]
Ozagrel 3.5 mmol/L
Model: male stroke-prone spontaneously hypertensive rats (SHRSP/Kpo)
Methods and source locations

Compound reported in the paper: Ozagrel

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Animals (S1); Methods > Experimental protocol > Protocol 2. Pathological roles of TXA2 together with oxidative stress (S12, S13, S22); Results > Pathological roles of TXA2 together with oxidative stress (S70)

urinary albumin excretion (UAE): urinary albumin excretion (UAE); comparator: untreated — Methods > Experimental protocol > Protocol 2. Pathological roles of TXA2 together with oxidative stress (S12, S13, S22); Results > Pathological roles of TXA2 together with oxidative stress (S70)

Ozagrel 3.5 mmol/L · Methods > Experimental protocol > Protocol 2. Pathological roles of TXA2 together with oxidative stress (S12, S13); Results > Pathological roles of TXA2 together with oxidative stress (S70)

Ozagrel and Myometrial Infiltration in Adenomyosis

Animal study · ICR mice; female mice; adenomyosis; Group L, n = 10; Group H, n = 10 [3]

Female ICR mice with adenomyosis received low- or high-dose Ozagrel by intraperitoneal administration. Compared with untreated mice, mice receiving either dose had significantly less myometrial infiltration.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
depth of myometrial infiltrationReported result compared with untreated mice, mice treated with either low- or high-dose Ozagrel had significantly less infiltration (both p-values <0.001; Fig. 2a); regression coefficient β = −0.956, p = 3.2×10−7[3]

Conditions shared by the study groups

Route
intraperitoneal (i.p.) administration
Treatment course
At the 16th week after birth; for 3 weeks, daily
Vehicle
0.9 % normal saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Ozagrel 12.5 μg/g; 25 μg/gGroup U (n = 9), or the untreated group, received the vehicle onlycompared with untreated mice, mice treated with either low- or high-dose Ozagrel had significantly less infiltration (both p-values <0.001; Fig. 2a); regression coefficient β = −0.956, p = 3.2×10−7[3]
Ozagrel 12.5 μg/g; 25 μg/g
Model: ICR mice; female mice; adenomyosis; Group L, n = 10; Group H, n = 10
Reported limits: Removed after verification: value.
Methods and source locations

Compound reported in the paper: Ozagrel

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Chemicals (S1); Methods > Animals and the procedure for induction of adenomyosis (S5, S9, S11); Methods > Experimental protocol (S16, S17); Results > Treatment effect on the depth of myometrial infiltration, hotplate latency, and uterine and bodyweight (S83, S84, S87)

depth of myometrial infiltration: depth of myometrial infiltration; comparator: Group U (n = 9), or the untreated group, received the vehicle only — Results > Treatment effect on the depth of myometrial infiltration, hotplate latency, and uterine and bodyweight (S83, S84, S87)

Ozagrel 12.5 μg/g; 25 μg/g · Methods > Experimental protocol (S16, S17); Results > Treatment effect on the depth of myometrial infiltration, hotplate latency, and uterine and bodyweight (S84, S87)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 82571-53-7
Applications TXAS inhibitor
Formula C13H12N2O2
Molecular Weight 228.25
Synonyms OKY-046
SMILES
C1=CC(=CC=C1CN2C=CN=C2)/C=C/C(=O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 44 mg/mL (192.77 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Ozagrel (OKY-046) Research References

  1. [1] Tomishima Y, Ishitsuka Y, Matsunaga N, et al. Ozagrel hydrochloride, a selective thromboxane A₂ synthase inhibitor, alleviates liver injury induced by acetaminophen overdose in mice. BMC Gastroenterol (2013). PMID: 23363429 DOI: 10.1186/1471-230X-13-21 Source material
  2. [2] Nakano Y, Nakatani Y, Takami M, et al. Diverse associations between oxidative stress and thromboxane A2 in hypertensive glomerular injury. Hypertens Res (2019). PMID: 30542084 DOI: 10.1038/s41440-018-0162-x Source material
  3. [3] Zhu B, Chen Y, Shen X, et al. Anti-platelet therapy holds promises in treating adenomyosis: experimental evidence. Reprod Biol Endocrinol (2016). PMID: 27724926 DOI: 10.1186/s12958-016-0198-1 Source material

Added to your cart

View Cart Checkout
Loading...